Sanofi, GlaxoSmithKline disclose DOJ investigation into Zantac after recalls

After global recalls of heartburn medicine Zantac and an FDA ban, the Department of Justice is investigating Sanofi and GlaxoSmithKline for possible violations of the False Claims Act.

The drugmakers last year pulled their Zantac products over an impurity believed to cause cancer, and Sanofi said the probe is over disclosures relating to that impurity. GSK didn't comment on the nature of the investigation, but a spokesman said the company is cooperating.